Esketamine Nasal Spray (Spravato) for Treatment-Resistant Depression
Esketamine Nasal Spray (Spravato) for Treatment-Resistant Depression
April 8, 2019 (Issue: 1569)
The FDA has approved esketamine (Spravato –
Janssen), an N-methyl-D-aspartate (NMDA) receptor
antagonist, for intranasal treatment (in conjunction
with an oral antidepressant) of adults with treatment-resistant
depression (TRD). This is the...more
- Drugs for depression. Med Lett Drugs Ther 2016; 58:85.
- G Sanacora et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 2017; 74:399.
- NR Williams et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry 2018; 175:1205.
- V Popova et al. S111. Randomized, double-blind study of flexibly-dosed intranasal esketamine plus oral antidepressant vs. active control in treatment-resistant depression. Biol Psychiatry 2018; 83:S390.
- E Daly et al. Esketamine nasal spray combined with an oral antidepressant for relapse prevention in treatment-resistant depression: results of a double-blind, randomized withdrawal, multicenter study (SUSTAIN-1). Poster presented at: European College of Neuropsychopharmacology (ECNP) Congress; October 7, 2018; Barcelona, Spain. Available at: https://2018.ecnp.eu. Accessed March 27, 2019.
- CM Canuso et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2018; 175:620.
- E Wajs et al. Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study. Poster presented at: European College of Neuropsychopharmacology (ECNP) Congress; October 6-9, 2018; Barcelona, Spain. Available at: https://2018.ecnp.eu. Accessed March 27, 2019.
- RL Morrison et al. Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study. Psychopharmacology (Berl) 2018; 235:1107.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Esketamine Nasal Spray (Spravato) for Treatment-Resistant Depression
Article code: 1569b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
